

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Geir HETLAND
Serial No. : 10/585,600
For : USE OF THE MUSHROOM AGARICUS BLAZEI MURILL
FOR THE PRODUCTION OF MEDICAMENTS SUITABLE
FOR TREATING INFECTIONS AND ALLERGIES
Filed :
Int'l Appln. No. : PCT/NO2005/000012
Int'l Filing Date : 21 July 2005 (21.07.2005)
Priority Filing Date : 12 January 2004 (12.01.2004)
25 October 2004 (25.10.2004)
Examiner : Not Yet Assigned
Art Unit : Not Yet Assigned
Confirmation No. : 8834

745 Fifth Avenue
New York, NY 10151
June 9, 2008

TRANSMITTAL OF SECOND INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR 1.97(B)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The second Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last. No fee is


required. The reference is listed on the enclosed Form 1449. Since the reference is a US patent application publication, the Applicant has not enclosed a copy. If the Examiner would like the Applicant to provide a copy of this reference, Applicant will do so.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.

The Commissioner is authorized to charge any additional fee that may be required to Deposit Account No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By:



Ronald R. Santucci
Reg. No. 28,988
(212) 588-0800